Vicore Pharma Holding AB is a high-risk pharmaceutical company based in Sweden. Specializing in severe lung diseases, Vicore Pharma is focused on developing a portfolio of treatments for respiratory conditions, including IPF. Their ESG score is 30.4, reflecting their commitment to environmental sustainability and governance. The company's C21 is a promising small molecule angiotensin II type 2 receptor agonist in phase 2a development for IPF. Additionally, Vicore Pharma is also working on Almee, a digital therapeutic device designed to address the psychological impact of living with pulmonary fibrosis. Experience cutting-edge treatments with Vicore Pharma Holding AB.